Viewing nowRosutin Tablet 5 mg (Rosuvastatin Calcium)
Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
Samchundang Pharmaceutical Co., Ltd.

MFDS item code 201405853 · Approved 2014.12.11 · Insurance code 651204210
Treatment of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
This medication is used as an adjunct to diet for patients with primary hypercholesterolemia and mixed hyperlipidemia who have difficulty in controlling their condition with diet and exercise alone. It is also helpful for patients with homozygous familial hypercholesterolemia along with diet or other lipid-lowering therapies. It effectively lowers total cholesterol and LDL-cholesterol, helping to delay the progression of atherosclerosis. It is also used as an adjunct to diet in patients with primary dysbetalipoproteinemia, aiding in the reduction of the risk of stroke, myocardial infarction, and vascular reinterventions in high-risk patients with cardiovascular disease risk factors. Thus, it improves cardiovascular health.
1. Primary hypercholesterolemia (type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.
This medication should not be administered to certain patients. It should not be used by individuals allergic to this medication, those with severe liver dysfunction, those with muscle disorders, those taking certain medications simultaneously, those with severely reduced kidney function, and women who are pregnant or breastfeeding. Women of childbearing potential should confirm that the possibility of being pregnant is low before using this medication and should use appropriate contraceptive methods. Additionally, individuals at high risk for muscle disorders should avoid high doses of this medication; risk factors include decreased kidney function, hypothyroidism, and family history. This medication contains lactose, so individuals with lactose intolerance should not take it. Individuals who consume large amounts of alcohol or have a history of liver disease should undergo periodic liver function tests, and those with hypothyroidism or nephrotic syndrome should treat the underlying conditions first. If symptoms such as myalgia or muscle weakness occur, they should inform healthcare providers immediately, and the medication may be discontinued if necessary. It is advisable to refrain from muscle enzyme tests when muscle damage occurs after exercise or due to other causes. In cases of acute severe illness or suspected severe renal failure, the use of this medication should be discontinued. This medication can rarely induce severe myasthenia gravis or ocular myasthenia; if these symptoms appear, use should be discontinued immediately. This medication may increase the risk of muscle adverse reactions when combined with other medications, especially when taken with fibrates. Kidney function tests may be necessary with high doses. In Asian individuals, increased body exposure to this medication may require dose adjustments. During therapy with this medication, liver function abnormalities, myalgia, headache, gastrointestinal disturbances, and other side effects, mostly mild and transient, may occur. However, serious adverse effects such as severe skin reactions, liver damage, and muscle rupture have also been reported; if symptoms appear, consulting a healthcare provider is essential. This medication should not be taken during pregnancy or while breastfeeding, and women planning pregnancy should use proper contraceptive methods. In case of overdose, there is no specific antidote, so treatment should be symptomatic, and liver function and muscle enzymes should be monitored periodically. Caution is advised as dizziness may occur while driving or operating machinery. This medication does not have any special carcinogenic risks, but it is important to report any abnormal symptoms during use and undertake regular examinations.
Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, discomfort in the chest, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering, and should be stored at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer period.
Yellow round film-coated tablet
Domestic use - 30 tablets/bottle, Domestic use - 100 tablets/bottle, Domestic use - 100 tablets/box [(10 tablets/Alu-Alu)x10]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 5.2mg
Tablet · Prescription medication
Samchundang Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.